Integrating BCMA Directed Bispecifics into the Relapsed / Refractory Myeloma Landscape

Explore the latest advancements in treating relapsed and refractory myeloma, including innovative therapies and their real-world applications.

Exploring the complexities of treating refractory myeloma patients, highlighting the significance of BCMA as a therapeutic target and innovative treatment options.

Drs Paul Richardson and Hans Lee walk through the pivotal LINKER-MM1 trial that supported the July 2025 approval of linvoseltamab for patients with relapsed or refractory multiple myeloma after multiple prior lines of therapy.

Drs Paul Richardson and Hans Lee focus on the safety profile of linvoseltamab and how its clinical features translate into real-world and community-based practice.

Drs Paul Richardson and Hans Lee focus on practical infection mitigation strategies for patients receiving BCMA-directed bispecific antibodies, with particular emphasis on the proactive use of intravenous immunoglobulin.

Drs Paul Richardson and Hans Lee compare the three currently available BCMA-directed bispecific antibodies and discuss how differences in administration, logistics, and emerging data influence treatment selection in relapsed or refractory multiple myeloma.

Drs Paul Richardson and Hans Lee address real-world strategies for managing cytokine release syndrome and how these considerations intersect with evolving treatment sequencing in multiple myeloma.

Drs Paul Richardson and Hans Lee discuss the evolving and often complex decisions around sequencing BCMA-directed therapies in multiple myeloma.

In this closing segment, Drs Paul Richardson and Hans Lee look ahead to how BCMA-directed bispecific antibodies may continue to evolve within an increasingly complex treatment landscape.